The GLP-1 clinical trial landscape is one were following with particular attention
However, given that neither hypothalamic (Nkx2.1 neurons), PVN (Sim1 neurons), nor POMC neurons were not necessary for the ability of long-acting agonists to reduced body mass (18), the hunt is still on for the specific population of neurons responsible for the pharmaceutical reduction in body mass
Even in a person with a slower metabolic rate due to hypothyroidism, reducing caloric intake through GLP-1-mediated satiety signals creates the deficit needed for weight loss
However, it is equally notable that GLP-1 R expression is reportedly undetectable in retinal and choroidal vasculature, the RPE, or other ocular structures [37]
However, access, cost, and coverage vary, making education and planning essential
After injection, the medication enters your bloodstream and begins binding to GLP-1 receptors in your gut and brain over the course of hours